

Systemic Sclerosis (Scleroderma) (Immunology) - Drugs in Development, 2021

<https://marketpublishers.com/r/SCF76C5D9570EN.html>

Date: March 2021

Pages: 489

Price: US\$ 2,500.00 (Single User License)

ID: SCF76C5D9570EN

Abstracts

Systemic Sclerosis (Scleroderma) (Immunology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis - Drugs in Development, 2021, provides an overview of the Systemic Sclerosis (Immunology) pipeline landscape.

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Sclerosis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development

by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 19, 11, 2, 40 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Systemic Sclerosis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Immunology).

The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Systemic Sclerosis (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Systemic Sclerosis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA)

and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Immunology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Systemic Sclerosis (Scleroderma) - Overview

Systemic Sclerosis (Scleroderma) - Therapeutics Development

Systemic Sclerosis (Scleroderma) - Therapeutics Assessment

Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development

Systemic Sclerosis (Scleroderma) - Drug Profiles

Systemic Sclerosis (Scleroderma) - Dormant Projects

Systemic Sclerosis (Scleroderma) - Discontinued Products

Systemic Sclerosis (Scleroderma) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Systemic Sclerosis (Scleroderma), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Companies, 2021 (Contd..2)
Number of Products under Development by Companies, 2021 (Contd..3)
Number of Products under Development by Companies, 2021 (Contd..4)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Target, 2021 (Contd..1)
Number of Products by Stage and Target, 2021 (Contd..2)
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2021 (Contd..2)
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Acceleron Pharma Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Accutis Pharmaceuticals Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by AKL Research and Development Ltd, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Allysta Pharmaceuticals Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Amgen Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by AnaMar AB, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals LLC, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Aryogen Pharmed Co, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by AstraZeneca Plc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Atlantic Healthcare Plc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Aurora Research Institute LLC, 2021

- Systemic Sclerosis (Scleroderma) - Pipeline by Avotres Inc, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Biogen Inc, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Biomendics LLC, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Blade Therapeutics Inc, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by BriaCell Therapeutics Corp, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Co, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Cantargia AB, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Castle Creek Biosciences Inc, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Celdara Medical LLC, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Centessa Pharmaceuticals Ltd, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Certa Therapeutics Pty Ltd, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by ChemomAb Ltd, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Chugai Pharmaceutical Co Ltd, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Civi Biopharma Inc, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by CohBar Inc, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Corbus Pharmaceuticals Inc, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by CSL Ltd, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Cumberland Pharmaceuticals Inc, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Cureveda LLC, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by D&D Pharmatech Co Ltd, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Emerald Health Sciences Inc, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Ergon Pharmaceuticals LLC, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Foresee Pharmaceuticals Co Ltd, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Fresenius Kabi SwissBioSim GmbH, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Galapagos NV, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Galecto Biotech ApS, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by GenKyoTex SA, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Genmab AS, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Gilead Sciences Inc, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline Plc, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by GNI Group Ltd, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by H. Lundbeck AS, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Horizon Therapeutics Plc, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by iBio Inc, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Ichnos Sciences Inc, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by Iltoo Pharma, 2021
- Systemic Sclerosis (Scleroderma) - Pipeline by ImmuneMed Inc, 2021

Systemic Sclerosis (Scleroderma) - Pipeline by Johnson & Johnson, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Kadmon Corp LLC, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Leadiant Biosciences Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Link Genomics Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Luminary Therapeutics Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by MDI Therapeutics Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Mitsubishi Tanabe Pharma Corp, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Ono Pharmaceutical Co Ltd, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Opsidio LLC, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Panorama Research Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Patagonia Pharmaceuticals LLC, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by PDX Pharmaceuticals LLC, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Peptinov SAS, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Pfizer Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Processa Pharmaceuticals Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by RadBio, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Regeneron Pharmaceuticals Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Resolys Bio Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Ribomic Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Riptide Bioscience Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Samumed LLC, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Seagen Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Signablok Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Talaris Therapeutics Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Timber Pharmaceuticals Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by TRACON Pharmaceuticals Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Tvardi Therapeutics Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Unity Biotechnology Inc, 2021
Systemic Sclerosis (Scleroderma) - Pipeline by Vicore Pharma AB, 2021
Systemic Sclerosis (Scleroderma) - Dormant Projects, 2021
Systemic Sclerosis (Scleroderma) - Dormant Projects, 2021 (Contd..1)
Systemic Sclerosis (Scleroderma) - Dormant Projects, 2021 (Contd..2)
Systemic Sclerosis (Scleroderma) - Discontinued Products, 2021
Systemic Sclerosis (Scleroderma) - Discontinued Products, 2021 (Contd..1)

List Of Figures

LIST OF FIGURES

Number of Products under Development for Systemic Sclerosis (Scleroderma), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

I would like to order

Product name: Systemic Sclerosis (Scleroderma) (Immunology) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/SCF76C5D9570EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SCF76C5D9570EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970